CYT-101 / Cyteph - LARVOL DELTA

TCaP: T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma (clinicaltrials.gov) - P1/2 | N=58 | Active, not recruiting | Sponsor: Queensland Institute of Medical Research | Recruiting ➔ Active, not recruiting | Trial primary completion date: Apr 2026 ➔ Oct 2025

Enrollment closed • Trial primary completion date • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • Cytomegalovirus Infection • Glioblastoma • Oncology • Solid Tumor

Cyteph Completes Recruitment for Phase I Clinical Trial of CYT-101 in Patients with Recurrent Glioblastoma Multiforme Brain Cancer (PRNewswire) - "The Phase I study is being conducted in collaboration with Briz Brain & Spine and Newro Foundation....The Phase I trial follows participants through dose-escalation cohorts, with key readouts expected at the end of Q4 2025."

Enrollment closed • P1 data • Glioblastoma